Sanofi: Citi Global Healthcare Conference (Sanofi) - Feb 27, 2013 - "Otamixaban is the first IV direct and selective factor Xa inhibitor with quick onset/offset; 27% to 42% risk reduction in ACS complications including death and MI in Phase Il"
P2 data • Acute Coronary Syndrome
|